Nordin M, Azemi A, Nordin A, Nabgan W, Ng P, Yusoff K
Pharmaceuticals (Basel). 2023; 16(7).
PMID: 37513835
PMC: 10386531.
DOI: 10.3390/ph16070923.
Saghari M, Gal P, Grievink H, Klaassen E, Itano A, McHale D
Front Immunol. 2022; 13:1009304.
PMID: 36582231
PMC: 9793106.
DOI: 10.3389/fimmu.2022.1009304.
Diaz-Dinamarca D, Salazar M, Castillo B, Manubens A, Vasquez A, Salazar F
Pharmaceutics. 2022; 14(8).
PMID: 36015297
PMC: 9414397.
DOI: 10.3390/pharmaceutics14081671.
Farag A, Gaynor J, Serena G, Ciancio G
BMC Surg. 2021; 21(1):74.
PMID: 33541328
PMC: 7863357.
DOI: 10.1186/s12893-021-01081-x.
Wimmers F, De Haas N, Scholzen A, Schreibelt G, Simonetti E, Eleveld M
Sci Rep. 2017; 7:43486.
PMID: 28344338
PMC: 5361210.
DOI: 10.1038/srep43486.
Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studies.
Swaminathan A, Lucas R, Dear K, McMichael A
Br J Clin Pharmacol. 2014; 78(5):1135-42.
PMID: 24833186
PMC: 4243888.
DOI: 10.1111/bcp.12422.
The treatment of disseminated vasculitis with methotrexate.
Mitchell M, Gifford R, Bertino J, Kenney J, Malawista S
Inflammation. 2013; 1(3):285-95.
PMID: 24194451
DOI: 10.1007/BF00917868.
Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.
Aarntzen E, de Vries I, Goertz J, Beldhuis-Valkis M, Brouwers H, van de Rakt M
Cancer Immunol Immunother. 2012; 61(11):2003-11.
PMID: 22527252
PMC: 3493659.
DOI: 10.1007/s00262-012-1263-z.
Response to cutaneous immunization with low-molecular-weight subunit keyhole limpet hemocyanin.
Milgrom H, Kesler K, Byron M, Harbeck R, Holliday R, Leung D
Int Arch Allergy Immunol. 2011; 157(3):269-74.
PMID: 22042247
PMC: 3224512.
DOI: 10.1159/000328784.
Monomorphic post-transplant lymphoproliferative disorder of the tongue: case report and review of literature.
Gonzalez-Cuyar L, Tavora F, Burke A, Gocke C, Zimrin A, Sauk J
Diagn Pathol. 2007; 2:49.
PMID: 18093326
PMC: 2231341.
DOI: 10.1186/1746-1596-2-49.
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
Gutierrez-Dalmau A, Campistol J
Drugs. 2007; 67(8):1167-98.
PMID: 17521218
DOI: 10.2165/00003495-200767080-00006.
Characterization of the impaired antipneumococcal polysacharide antibody production in immunosuppressed pediatric patients following cardiac transplantation.
Gennery A, Cant A, Baldwin C, Calvert J
J Clin Immunol. 2001; 21(1):43-50.
PMID: 11321238
DOI: 10.1023/a:1006793032290.
Tumour induction as a consequence of immunosuppression after renal transplantation.
Winter P, Schoeneich G, Miersch W, Klehr H
Int Urol Nephrol. 1997; 29(6):701-9.
PMID: 9477370
DOI: 10.1007/BF02552189.
The use of therapeutic drug monitoring to optimise immunosuppressive therapy.
Tsunoda S, Aweeka F
Clin Pharmacokinet. 1996; 30(2):107-40.
PMID: 8906895
DOI: 10.2165/00003088-199630020-00003.
Azathioprine metabolism in kidney transplant recipients.
Lennard L, Brown C, Fox M, Maddocks J
Br J Clin Pharmacol. 1984; 18(5):693-700.
PMID: 6391532
PMC: 1463549.
DOI: 10.1111/j.1365-2125.1984.tb02531.x.
Immunosuppressive therapy for renal transplantation.
Carpenter C, Strom T
Springer Semin Immunopathol. 1984; 7(1):43-57.
PMID: 6234670
DOI: 10.1007/BF01891779.
Hodgkin's disease complicated by infection with Mycobacterium kansasii.
Harris J, Alexanian R, Hersh E, Leary W
Can Med Assoc J. 1969; 101(4):231-4.
PMID: 5811703
PMC: 1946123.
Studies on the anti-inflammatory action of 6-mercaptopurine.
Hurd E, ZIFF M
J Exp Med. 1968; 128(4):785-800.
PMID: 5675437
PMC: 2138536.
DOI: 10.1084/jem.128.4.785.
Cyclophosphamide in the nephrotic syndrome of childhood: its use in two groups of patients defined by clinical, light microscopic and immunopathologic findings.
DRUMMOND K, Hillman D, MARCHESSAULT J, Feldman W
Can Med Assoc J. 1968; 98(11):524-31.
PMID: 5643296
PMC: 1923912.
Immunosuppressive therapy.
Chandra R
Indian J Pediatr. 1967; 34(238):421-3.
PMID: 5594846
